Literature DB >> 31993685

Less is more: a cost benefit analysis of a changed posology for nivolumab.

N W Boone1, A A van Bodegraven2.   

Abstract

Year:  2020        PMID: 31993685     DOI: 10.1007/s00228-020-02839-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  2 in total

1.  Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?

Authors:  Arnaud Bayle; Benjamin Besse; Maxime Annereau; Julia Bonastre
Journal:  Eur J Cancer       Date:  2019-04-06       Impact factor: 9.162

Review 2.  Fixed Dosing of Monoclonal Antibodies in Oncology.

Authors:  Jeroen J M A Hendrikx; John B A G Haanen; Emile E Voest; Jan H M Schellens; Alwin D R Huitema; Jos H Beijnen
Journal:  Oncologist       Date:  2017-07-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.